FC
VRDN icon

Farringdon Capital’s Viridian Therapeutics VRDN Stock Holding History

Farringdon Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,152
Closed -$329K – 615
2024
Q4 		$329K Buy
+17,152
New +$373K 0.14% 246

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Farringdon Capital's VRDN Position: Q1 2025 in Review

Farringdon Capital sold out of Viridian Therapeutics (VRDN) in Q1 2025, closing a stake of 17,152 shares — an estimated $329K sold.

Farringdon Capital first reported a position in VRDN in Q4 2024 and held it in 1 quarter. The position peaked at $329K in Q4 2024. 176 funds tracked by Wall St. Rank hold VRDN as of Q1 2025.

  • Farringdon Capital reported no remaining Viridian Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Farringdon Capital sold 17,152 Viridian Therapeutics shares in Q1 2025, an estimated $329K.
  • Farringdon Capital first reported a position in Viridian Therapeutics in Q4 2024 and held it in 1 quarter.
  • Farringdon Capital's Viridian Therapeutics position peaked at $329K in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2025.

Based on Farringdon Capital's 13F filing for Q1 2025, filed 15 May 2025.